Literature DB >> 20191615

Interleukin-34 is expressed by giant cell tumours of bone and plays a key role in RANKL-induced osteoclastogenesis.

Marc Baud'huin1, Romain Renault, Céline Charrier, Anne Riet, Anne Moreau, Régis Brion, François Gouin, Laurence Duplomb, Dominique Heymann.   

Abstract

Interleukin-34 (IL-34) is a newly discovered regulator of myeloid lineage differentiation, proliferation, and survival, acting via the macrophage-colony stimulating factor receptor (M-CSF receptor, c-fms). M-CSF, the main ligand for c-fms, is required for osteoclastogenesis and has been already identified as a critical contributor of the pathogenesis of giant cell tumours of bone (GCTs), tumours rich in osteoclasts. According to the key role of M-CSF in osteoclastogenesis and GCTs, the expression of IL-34 in human GCTs was first assessed. Quantitative analysis of IL-34 mRNA expression in 14 human GCTs revealed expression of this cytokine in GCTs as well as M-CSF and c-fms. Immunohistochemistry demonstrated that osteoclast-like cells exhibited a huge immunostaining for IL-34 and that mononuclear stromal cells were slightly positive for this protein. In contrast to osteoblasts, bone-resorbing osteoclasts showed very strong staining for IL-34, suggesting its potential role in the pathogenesis of GCTs by facilitating osteoclast formation. The role of IL-34 in osteoclastogenesis was then studied in murine and human models. IL-34 was able to support RANKL-induced osteoclastogenesis in the absence of M-CSF in all models. Multinucleated cells generated in the presence of IL-34 and RANKL expressed specific osteoclastic markers and resorbed dentine. IL-34 induced phosphorylation of ERK 1/2 and Akt through the activation of c-fms, as revealed by the inhibition of signalling by a specific c-fms tyrosine kinase inhibitor. Furthermore, IL-34 stimulated RANKL-induced osteoclastogenesis by promoting the adhesion and proliferation of osteoclast progenitors, and had no effect on osteoclast survival. Overall, these data reveal that IL-34 can be entirely substituted for M-CSF in RANKL-induced osteoclastogenesis, thus identifying a new biological activity for this cytokine and a contribution to the pathogenesis of GCTs. Copyright (c) 2010 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20191615     DOI: 10.1002/path.2684

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  50 in total

1.  Proteoglycans and osteolysis.

Authors:  Marc Baud'Huin; Céline Charrier; Gwenola Bougras; Régis Brion; Frédéric Lezot; Marc Padrines; Dominique Heymann
Journal:  Methods Mol Biol       Date:  2012

2.  Interleukin-34 induces monocytic-like differentiation in leukemia cell lines.

Authors:  Burthia E Booker; Ryan S Clark; Samuel T Pellom; Samuel E Adunyah
Journal:  Int J Biochem Mol Biol       Date:  2015-03-20

3.  Baseline serum interleukin-34 levels independently predict radiographic progression in patients with rheumatoid arthritis.

Authors:  Sung Hae Chang; Byoong Yong Choi; Jungbum Choi; Jong Jin Yoo; You-Jung Ha; Hyon Joung Cho; Eun Ha Kang; Yeong Wook Song; Yun Jong Lee
Journal:  Rheumatol Int       Date:  2014-06-11       Impact factor: 2.631

Review 4.  Galectin-3 in bone tumor microenvironment: a beacon for individual skeletal metastasis management.

Authors:  Kosei Nakajima; Dong Hyo Kho; Takashi Yanagawa; Melissa Zimel; Elisabeth Heath; Victor Hogan; Avraham Raz
Journal:  Cancer Metastasis Rev       Date:  2016-06       Impact factor: 9.264

5.  Interleukin 34 expression is associated with synovitis severity in rheumatoid arthritis patients.

Authors:  M Chemel; B Le Goff; R Brion; C Cozic; M Berreur; J Amiaud; G Bougras; S Touchais; F Blanchard; M F Heymann; J M Berthelot; F Verrecchia; D Heymann
Journal:  Ann Rheum Dis       Date:  2011-10-28       Impact factor: 19.103

6.  Differentiation-dependent antiviral capacities of amphibian (Xenopus laevis) macrophages.

Authors:  Amulya Yaparla; Milan Popovic; Leon Grayfer
Journal:  J Biol Chem       Date:  2017-12-19       Impact factor: 5.157

Review 7.  Functions of interleukin-34 and its emerging association with rheumatoid arthritis.

Authors:  Ren-Peng Zhou; Xiao-Shan Wu; Ya-Ya Xie; Bei-Bei Dai; Wei Hu; Jin-Fang Ge; Fei-Hu Chen
Journal:  Immunology       Date:  2016-09-23       Impact factor: 7.397

8.  IL-34 is a Treg-specific cytokine and mediates transplant tolerance.

Authors:  Séverine Bézie; Elodie Picarda; Jason Ossart; Laurent Tesson; Claire Usal; Karine Renaudin; Ignacio Anegon; Carole Guillonneau
Journal:  J Clin Invest       Date:  2015-09-21       Impact factor: 14.808

Review 9.  Osteoclasts-Key Players in Skeletal Health and Disease.

Authors:  Deborah Veis Novack; Gabriel Mbalaviele
Journal:  Microbiol Spectr       Date:  2016-06

Review 10.  Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies.

Authors:  Ingrid Lilienthal; Nikolas Herold
Journal:  Int J Mol Sci       Date:  2020-09-19       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.